NYU Langone Health researchers created a mouse model of X-linked dystonia-parkinsonism by inserting a disease-linked human gene segment into part of the mice’s Taf1 gene, providing a faster setting to study the rare neurodegenerative disease.
The 78-kilobase segment contained an SVA_F insertion associated with XDP in the TAF1 gene, according to a bioRxiv preprint. The researchers used a partly humanized version of the mouse gene. The preprint reports reduced TAF1 expression, severe atrophy centered on the striatum and death in affected male mice by two months of age.
XDP is an adult-onset disease associated with movement disorders that worsen over time, NYU Langone said in a Nov. 19 announcement. The SVA insertion is within the gene. The researchers say it can impede transcription, the process by which DNA is used to produce RNA, and reduce TAF1 expression.
The sources give different estimates of how quickly the disease develops. NYU Langone’s announcement says symptoms appeared in mice in 1.5 months, compared with 30 years in people; the preprint gives two months in mice and 50 years in people. The sources do not reconcile the difference.
In a separate experiment, researchers used CRISPRa to increase activity of the humanized TAF1 gene in embryonic stem cells. The preprint reports that the intervention restored cell viability. The experiment was conducted in cells; the supplied sources report no treatment result in living animals or patients.
Jef D. Boeke, the study’s senior author and director of NYU Langone’s Institute for Systems Genetics, said the findings provide a basis for exploring therapeutic approaches. The authors say the approach could also help researchers build models for rare diseases linked to changes in noncoding DNA. The preprint presents this as a potential research use.


